Physician profile
Howard Abrams
NPI 1265459978
$2,068.44
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,070 · 2020: $307 · 2021: $601 · 2022: $62.98 · 2024: $27.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $27.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $27.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $812.87 | 2019-2022 | |
| Janssen Biotech, INC. | $328.59 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $278.57 | 2019-2021 | |
| Abbvie INC. | $150.77 | 2019-2021 | |
| Pfizer INC. | $143.42 | 2019 | |
| Ironwood Pharmaceuticals, INC | $132.32 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $42.45 | 2021 | |
| Shionogi INC | $32.63 | 2019 | |
| Abbott Laboratories | $27.06 | 2024 | Proclaim |
| Amag Pharmaceuticals, INC. | $26.55 | 2019-2020 | |
| Gilead Sciences, INC. | $23.60 | 2019 | |
| Merck Sharp & Dohme LLC | $22.52 | 2020-2021 | |
| Ultragenyx Pharmaceutical INC. | $18.28 | 2020 | |
| Celgene Corporation | $16.48 | 2021 | |
| Shire North American Group INC | $12.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Abrams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.